MedTrace Logo

Simultaneous Study of the Serum Tryptase Level of the Mother and the Child During Childbirth (TryPla)

NCT04441463 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-06-22

No results posted yet for this study

Summary

Currently the neonatal serum level of severals proteins can be used as an indicator of subsequent risk. For example, we plan to explore the neonatal kinetics of tryptase and other immune proteins as potential markers for the risk of postnatal complications, particularly in premature babies. However, today no study has shown whether the tryptase level in the newborn is a reflection of fetal synthesis alone, or that of the mother by possible transplacental passage. There is also no database that has defined normal values for tryptase in cord blood.

Our main objective is to determine the correlation between the level of maternal tryptase and that of the newborn in cord blood immediately after birth in order to estimate the transplacental passage of this molecule.

Conditions

  • Newborn
  • Parturient

Interventions

BIOLOGICAL

Blood sampling for tryptase analysis

3 bloods test * One blood sample taking from the mother's vein punction, during the delivery. * One blood sample tanking from umbilical cord. * One blood sample taking from the baby in day 3 of life, during the Guthrie test.

Sponsors & Collaborators

  • University Hospital, Clermont-Ferrand

    lead OTHER

Principal Investigators

  • Maguelonne Pons · University Hospital, Clermont-Ferrand

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2020-11-30
Completion
2020-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04441463 on ClinicalTrials.gov